A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy
Cancer Chemotherapy and PharmacologyPublished 1 January 1992
Tetsu Shinkai, Kenji Eguchi, Yasutsuna Sasaki, Tomohide Tamura, Yuichiro Ohe, Akira Kojima
Citations53
SJR quartileQ1
SJR score0.97
SNIP0.79
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A prognostic index for survival was used to define three prognostic groupings (good, intermediate, and poor) for survival and demonstrated that squamous-cell histology, early stage, and a small number of metastatic sites were favorable prognostic factors for response to chemotherapy.
Abstract
Prognostic factors for response and survival were retrospectively evaluated in 192 previously untreated patients with advanced non-small-cell lung cancer (NSCLC) who had received either vindesine plus cisplatin or mitomycin plus vindesine plus cisplatin as initial treatment. Univariate analysis demonstrated that squamous-cell histology, early stage, and a small number of metastatic sites were favorable prognostic factors for response to chemotherapy. Multivariate analysis using Cox's proportional hazard model indicated that the number of metastatic sites was the only significant pretreatment factor for response (P = 0.0005). Multivariate regression analysis revealed that the number of metastatic sites (P = 0.0002), sex (P = 0.0009), serum albumen levels (P = 0.0018), performance status (P = 0.0026) and lactic dehydrogenase values (P = 0.0026) contributed independently to survival. On the basis of these five prognostic factors, a prognostic index for survival was used to define three prognostic groupings (good, intermediate, and poor) for survival (median survival, 16.5 vs 9.4 vs 4.6 months; P = 0.0001). This particular regression model should aid in the design and analysis of new treatment strategies and may be useful for indirect comparisons of different studies carried out in similar patient populations.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
Springer series in statisticsNonparametric Estimation from Incomplete Observations
45,533 Citations1992Edward L. Kaplan, Paul Meier
Journal of the Royal Statistical Society Series B (Statistical Methodology)Regression Models and Life-Tables
39,259 Citations1972D. R. Cox
Journal of the American Statistical AssociationNonparametric Estimation from Incomplete Observations
39,052 Citations1958Edward L. Kaplan, Paul Meier
CHEST JournalA New International Staging System for Lung Cancer
1,665 Citations1986Clifton F. Mountain
The International Staging System for Lung Cancer provides for classification of six levels of disease extent in five stage groups that relate to patient management and prognosis and can be readily applied in a broad spectrum of clinical and teaching environments.
BiometrikaEstimation of the probability of an event as a function of several independent variables
1,621 Citations1967Strother H. Walker, David B. Duncan
A recursive approach based on Kalman's work in linear dynamic filtering and prediction is applied, derivable also from the work of Swerling (1959), which provides an example of many other possible uses of recursive techniques in nonlinear estimation and in related areas.
Journal of Chronic DiseasesAppraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
1,040 Citations1960C. Gordon Zubrod, Marvin A. Schneiderman +17 more
A comparative study of triethylene thiophosphoramide and nitrogen mustard in cancer of the lung and breast, melanoma, and Hodgkin's disease concludes that thio-TEPA was less active than HN2 (in the doses used) in inducing remissions.
Journal of Clinical OncologyChemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
700 Citations1988E Rapp, Joseph L. Pater +8 more
A prospective randomized trial comparing best supportive care (BSC) to two chemotherapy regimens, vindesine and cisplatin (VP), and cyclophosphamide, doxorubicin, and cis platin (CAP), and found that the treatment groups were comparable in terms of age, sex, performance status, histology, disease extent, and weight loss.
PubMedRegression models for prognostic prediction: advantages, problems, and suggested solutions.
566 Citations1985Harrell Fe, Lee Kl +2 more
Regression models can make more accurate predictions than other methods such as stratification and recursive partitioning, when model assumptions are thoroughly examined; steps are taken when assumptions are violated; and the method of model formulation does not result in overfitting the data.
JNCI Journal of the National Cancer InstitutePrognostic Factors for Survival in Patients With Inoperable Lung Cancer<xref ref-type="fn" rid="FN2">2</xref>
565 Citations1980Kenneth Stanley
The three most important prognostic factors affecting survival were the Karnofsky initial performance status score, extent of disease, and weight loss in the previous 6 months.
Journal of Clinical OncologyA randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
343 Citations1986John C. Ruckdeschel, Dianne M. Finkelstein +5 more
Analysis of the toxicity data showed that most of the severe toxicity occurred in the 19% of patients who were initially PS 2, suggesting that they are not appropriate candidates for trials of new agents or combinations.
Journal of Clinical OncologyLong-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
324 Citations1986Dianne M. Finkelstein, David S. Ettinger +1 more
A detailed chart review of 32 2-year survivors and 32 matched controls demonstrated that maintenance or improvement of performance status and maintenance of serum albumin levels at 3 months from the initiation of treatment were both important predictors of longer survival.
PubMedThe effect of bronchitis, smoking, and occupation on ventilation.
292 Citations1963G. L. Brinkman, E O COATES
This study was confined to men working full time, and selection of the men depended to a great extent on their availability, resulting in a haphazard sampling, but there is no reason to believe that this has introduced any particular bias.
Lung CancerStaging and prognostic factors in small cell lung cancer: a consensus report
267 Citations1989Rolf A. Stahel, Robert J. Ginsberg +8 more
‘Division of Oncology, Department of Medicine, University Hospital, Zitrich (Switzerland) and ‘ODepartment of Radiotherapy, Inrtitut Jules Bordet’.
Journal of Clinical OncologyFrequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.
241 Citations1986Joseph O’Connell, Mark G. Kris +7 more
Information from this analysis may be useful when comparing the response data of completed studies in similar patients, in designing future trials, and in the selection of cisplatin plus vinca alkaloid therapy for individual patients with advanced NSCLC.
PubMedPrognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy.
115 Citations1981Daniel C. Ihde, Robert Makuch +5 more
In patients with small cell carcinoma whose disease is thoroughly staged and who are given aggressive chemotherapy, certain sites or a small number of sites of extensive disease may be treated as successfully as limited disease.
PubMedBrief overview of combination chemotherapy in non-small-cell lung cancer.
77 Citations1986R J Spiegel
The Clinical development of the recombinant alpha interferons represents a prototype for the clinical development of biological compounds and there is a suggestion of dose-response relationships, and a clearer picture of schedule dependence.
Journal of Clinical OncologyOutcome of patients with small-cell lung cancer: effect of changes in staging procedures and imaging technology on prognostic factors over 14 years.
68 Citations1990Matthew P. Dearing, S. M. Steinberg +5 more
It is concluded that the sensitivity of the staging procedures used can affect the impact on survival of cancer involvement of a given site and patients with cancer confined to their chest with medical or anatomic contraindications to chest radiotherapy do not have a shorter survival than patients with limited-stage disease treated with chemotherapy alone.
Lung CancerPrognostic factors in inoperable adenocarcinoma of the lung: A multivariate regression analysis of 259 patients
68 Citations1990Jonas Sørensen
Journal of Clinical OncologyEffect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study.
49 Citations1986Thomas P. Miller, T T Chen +7 more
Survival was significantly longer for fully ambulatory FOMi/CAP-treated patients compared with either Fomi or CAP, and younger patients treated with full doses of therapy responded more often than older patients receiving reduced drug doses.
Lung CancerComparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer
46 Citations1986T Shinkai, N. Saijo +6 more
The combination of vindesine and cisplatin appears to be effective against advanced non-small cell lung cancer.
Journal of Clinical OncologyChemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.
40 Citations1987Jens Benn Sørensen, H.H. Hansen +6 more
The VDS single-agent activity in ACL was confirmed, but addition of VDS to the three-drug regimen did not increase activity, and comparison to a matched control group on supportive care is indicated.
Journal of Cancer Research and Clinical OncologyPrognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital (Japan)
33 Citations1987Masanori Sakurai, Tetsu Shinkai +11 more
Analysis retrospectively of patients with unresectable non-small cell lung cancer using eight pretreatment and three treatment-related prognostic factors found that performance status, sex, and treatment period after CDDP proved to be important factors for long-term survival.
PubMedCisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.
32 Citations1986Tetsu Shinkai, Nagahiro Saijo +8 more
Combination chemotherapy with cisplatin and vindesine showed significant antitumor activity in patients with non-small cell lung cancer, however, the high-dose regimen of cisPlatin did not result in a significantly better response rate or survival advantage, and was associated with greater toxicity.
European Journal of Cancer and Clinical OncologyA randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer
28 Citations1991Tetsu Shinkai, Kenji Eguchi +6 more
The addition of mitomycin to the VP regimen appears to have limited value in advanced NSCLC, with no difference in the frequency of side-effects observed.